Evidence map›Paper›PMID 41383556›Full record

ReviewBJR open2025

Exploring the therapeutic potential of localized alpha irradiation for cancer: from DNA damage to immune activation.

Saskia Hazout, Daniel Zwahlen, Christoph Oehler, Ambroise Champion, David Benzaquen, Daniel Taussky

Abstract readReview
In one paragraph

Review in BJR open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Saskia HazoutDepartment of Radiation Oncology, Centre Hospitalier de l'Université de Montréal-CHUM, Montreal, QC H2X 0C1, Canada.
Daniel ZwahlenDepartment of Radiation Oncology, Kantonsspital Winterthur, Winterthur, ZH 8401, Switzerland.
Christoph OehlerDepartment of Radiation Oncology, Kantonsspital Winterthur, Winterthur, ZH 8401, Switzerland.
Ambroise ChampionRadiation Oncology, Hôpital de La Tour, Meyrin, Meyrin, GE 1217, Switzerland.
David BenzaquenRadiation Oncology, Hôpital de La Tour, Meyrin, Meyrin, GE 1217, Switzerland.
Daniel TausskyDepartment of Radiation Oncology, Centre Hospitalier de l'Université de Montréal-CHUM, Montreal, QC H2X 0C1, Canada.ORCID https://orcid.org/0000-0001-5267-3213

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alpha radiation has emerged as a promising modality in cancer treatment due to its unique physical and biological properties. Among these, diffusing alpha-emitters radiation therapy (DaRT) delivers alpha radiation directly into solid tumours using inserted seeds. This review synthesizes both the biological mechanisms and therapeutic implications of alpha irradiation, with a focus on DaRT. We explore how alpha particles induce complex DNA damage, modulate the tumour microenvironment, and interact with immune therapies. Emphasis is placed on preclinical and early clinical findings that suggest DaRT's potential to improve outcomes, especially in difficult-to-treat malignancies. The high linear energy transfer (LET) radiation induces complex DNA damage in tumour cells, leading to increased cell death compared to conventional radiotherapy. Alpha particles have a short range in tissue, allowing for highly localized treatment with minimal damage to surrounding healthy tissue. Recent studies have demonstrated that alpha radiation can stimulate antitumor immune responses, potentially enhancing treatment efficacy. Clinical trials utilizing alpha-emitting radioisotopes have shown encouraging results in various cancer types, particularly for metastatic disease.

Indexed as

alpha irradiationDaRTDSBLET

Identifiers

PMID41383556
PMCPMC12694430

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.